Citations

Clear

6055 citation(s) found for "Vu, Peter".

Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression
Graff‐Radford, Jonathan , Przybelski, Scott A. , Wiste, Heather J. , Reichard, Ross R., Fields, Julie A. , Nelson, Peter T. , Lowe, Val J. , Petersen, Ronald C. , Corriveau‐Lecavalier, Nick , Botha, Hugo , Switzer, Aaron , Murray, Melissa E. , Dickson, Dennis W. , Nguyen, Aivi T. , Ramanan, Vijay K. , McCarter, Stuart J. , Boeve, Bradley F. , Machulda, Mary M. , Stricker, Nikki H. , Grothe, Michel J. , Knopman, David S. , Jack, Clifford R. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.084087 Get It

AbstractBackgroundLimbic‐predominant age‐related TDP‐43 encephalopathy (LATE) is a neuropathologically‐defined disease, and it is frequently comorbid with Alzheimer’s disease neuropathological change (ADNC). However, the neurological syndrome associated with LATE neuropathological change (LATE‐NC) is not defined. We propose a set of clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome (LANS) that is highly associated with LATE‐NC. These criteria assess degree of certainty (highest, high, moderate, low) based on features that are measurable in vivo, including older age at evaluation, a mild clinical syndrome, impaired semantic knowledge, disproportionate hippocampal atrophy, limbic hypometabolism, absence of neocortical degeneration patterns and low likelihood of neocortical tau. We operationalized these criteria using two large datasets with clinical and pathologic outcomes.MethodWe screened autopsied patients from Mayo Clinic and ADNI cohorts and applied the LANS criteria to those with an antemortem predominant amnestic syndrome (Mayo, n = 165; ADNI, n = 53). We compared frequencies of neuropathological diagnoses across LANS likelihoods, compared longitudinal CDR‐SB trajectories across LANS likelihoods, and stratified ADNC/LATE‐NC patients according to their LANS likelihood and compared their longitudinal CDR‐SB trajectories to those with ADNC or LATE‐NC.ResultADNC, ADNC/LATE‐NC and LATE‐NC accounted for 35%, 37% and 4% of cases in the Mayo cohort, respectively, and 30%, 22%, and 9% of cases in the ADNI cohort, respectively (Fig. 1). ADNC cases had the lowest LANS likelihoods, LATE‐NC patients had the highest likelihoods, and ADNC/LATE‐NC patients had intermediate likelihoods. Patients with high LANS likelihoods had a milder and slower clinical course and more severe temporo‐limbic degeneration compared to those with low likelihoods (Fig. 2). ADNC/LATE‐NC patients with higher likelihoods had more temporo‐limbic degeneration and a slower rate of cognitive decline, and those with lower likelihoods had more lateral temporo‐parietal degeneration and a faster rate of cognitive decline (Fig. 3).ConclusionThe implementation of LANS criteria has implications for disambiguating the different driving etiologies of progressive amnestic presentations in older age to guide prognosis, treatment, and clinical trial design and enrollment. The development of in vivo biomarkers specific to TDP‐43 pathology are needed to further refine molecular associations between LANS and LATE‐NC and precise antemortem diagnoses of LATE.
Craniofacial Pain Locations and Outcomes After Endoscopic Sinus Surgery for Unilateral Sphenoid Sinusitis: A Multi‐Institutional Study
Eide, Jacob G. , Pellizzari, Richard , Saibene, Alberto Maria , Donato, Luigi De, Bitner, Benjamin F. , Wei, Kimberly , Panara, Kush , Kshirsagar, Rijul S. , Whitehead, Russell A. , Filip, Peter , Papagiannopoulos, Peter , Tajudeen, Bobby A. , Adappa, Nithin D. , Saibene, Alberto M , Bitner, Benjamin , Kshirsagar, Rijul S , Douglas, Jennifer E , Filip, Peter , Kuan, Edward C , Craig, John R , Eide, Jacob G , Lee, Daniel J. , Adappa, Nithin D. , Craig, John R.

Mayo Clinic

The Laryngoscope | January 3, 2025 | Volume: 135 | Issue: 6 | Pages: 1915-1919

10.1002/lary.31985 | PMID 39749758 Get It

IntroductionUnilateral sphenoid sinus opacification on computed tomography is caused by a variety of pathologies including inflammatory and infectious sinusitis, benign and malignant tumors, and encephaloceles. The purpose of this study was to report craniofacial pain locations and outcomes in inflammatory unilateral sphenoid sinusitis (USS) patients who underwent endoscopic sinus surgery (ESS).MethodsA multi‐institutional retrospective cohort study was conducted on all adult patients who had ESS for USS from 2015 to 2022. Patient demographics, presenting symptoms and nasal endoscopy findings, extent of surgical dissection, and craniofacial pain locations and outcomes were recorded. Exclusion criteria included age <18 years, non‐inflammatory etiology, immunodeficiency, invasive fungal sinusitis, lack of follow‐up, lack of preoperative pain location, and neoplasia. Descriptive statistics were calculated.ResultsOf 57 patients with USS, 44 (77.2%) reported craniofacial pain at one or more locations. Retrobulbar (n = 19, 43.2%) was the most common pain location followed by frontal (n = 17, 38.6%) and occipital (n = 10, 22.7%). Surgical intervention resulted in pain resolution in 33/44 patients (75%), with a mean follow‐up of 83.7 (±97.8) days. There were no significant associations between presenting symptoms, imaging findings, endoscopy, surgical extent, or final pathology and the presence or resolution of facial pain (p > 0.05).ConclusionIn USS patients, the most common craniofacial pain locations were retrobulbar, occipital, and frontal, with a minority being vertex. Based on short‐term follow‐up, ESS resolved the craniofacial pain in 75% of cases. There were no clinical variables that predicted the presence or resolution of craniofacial pain.Level of Evidence4 Laryngoscope, 135:1915–1919, 2025
Postoperative Implementation of Virtual Reality and Wearable Devices: Opportunities and Challenges
Pandrangi, Vivek C. , Araujo, Ana V. , Buncke, Michelle , Olson, Brennan , Jorizzo, Matthew , Said‐Al‐Naief, Nasser, Sanusi, Olabisi , Ciporen, Jeremy , Shindo, Maisie L., Schindler, Joshua S. , Colaianni, C. Alessandra , Flint, Paul W., Wax, Mark K. , Li, Ryan J. , Clayburgh, Daniel , Wax, Mark K , Geltzeiler, Mathew , Olson, Brennan G , Andersen, Peter E. , Geltzeiler, Mathew

Mayo Clinic

The Laryngoscope | January 3, 2025 | Volume: 135 | Issue: 6 | Pages: 2044-2050

10.1002/lary.31989 | PMID 39749757 Get It

ObjectiveTo examine implementation of virtual reality (VR) and Fitbit wearable activity devices in postoperative recovery.MethodsThis was a prospective, 4‐arm, randomized controlled trial of patients undergoing inpatient head and neck surgery at a tertiary academic center from November 2021 to July 2022. Patients were randomized to Control, VR, Fitbit, or combined VR + Fitbit groups. Patients in the VR groups were brought VR headsets to use throughout each day, and patients in the Fitbit groups wore Fitbit devices and were encouraged to achieve 2,000 daily steps. The primary outcome was average daily opioid use, measured as milligram morphine equivalents (MME).ResultsThere were 80 patients included. The majority of patients were male (68.8%), and mean age was 58.8 ± 14.4 years. Only the combined VR + Fitbit cohort was associated with reduced average daily opioid use (VR + Fitbit: 8.8 [20.6] MME vs. Control: 26.4 [37.4] MME, p = 0.02). Patients in intervention groups also had higher hospital satisfaction (p = 0.02). VR was utilized 26% of the time it was provided, with mean use time of 23.8 ± 7.8 min. Mean post‐VR subjective pain reduction was 1.0 ± 1.3, and there were three mild adverse events of neck or nasal discomfort. Among the Fitbit groups, there were no adverse events and daily step counts ≥2,000 steps were achieved 45% of the time.ConclusionImplementation of VR and wearable activity devices in postoperative recovery appears well tolerated and may facilitate further development of Enhanced Recovery After Surgery (ERAS) protocols, though there are challenges to maximizing device usage.Level of Evidence2 Laryngoscope, 135:2044–2050, 2025
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
Daw, Stephen , Cole, Peter D. , Garnier, Nathalie , Buffardi, Salvatore, Mascarin, Maurizio , Lissat, Andrej , Mauz‐Körholz, Christine , Krajewski, Jennifer , Akyol, Alev, Crowe, Russell, Drachtman, Richard A. , Kelly, Kara M. , Leblanc, Thierry , Harker‐Murray, Paul , Hoppe, Bradford S. , Hodgson, David , Beishuizen, Auke , Anderson, Bailey , Xu, Yan , Leblanc, Thierry

Mayo Clinic

JAMA Oncology | January 2, 2025 | Volume: 11 | Issue: 3 | Pages: 249

10.1001/jamaoncol.2024.5627 | PMID 39745739 Get It

ImportanceRetrieval strategies for children, adolescents, and young adults with relapsed classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic effects. Children, adolescents, and young adults with low-risk, relapsed cHL may benefit from replacing high-dose chemotherapy and autologous stem cell transplant with less intensive involved-site radiotherapy (ISRT).ObjectiveTo evaluate a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed cHL with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response and ISRT (30.0 to 30.6 Gy).Design, Setting, and ParticipantsCheckMate 744 (R1 cohort) was a phase 2, nonrandomized, single-arm study enrolling children, adolescents, and young adults aged 5 to 30 years with low-risk cHL between September 25, 2017, and December 16, 2020, across the US, Canada, and Europe. Data were analyzed from September 2017 to November 2022.ExposuresPatients received 4 cycles of nivolumab plus BV induction; patients with complete metabolic response (CMR) received an additional 2 cycles of nivolumab plus BV while patients with suboptimal response received 2 cycles of BV plus bendamustine intensification. Patients with CMR after induction or intensification received ISRT consolidation.Main Outcomes and MeasuresPrespecified coprimary end points were CMR rate (Lugano 2014 classification) any time before ISRT and 3-year event-free survival (EFS) rate, per blinded independent central review (BICR).ResultsOf 28 included patients treated in the low-risk cohort, 18 (64%) were female, and the median (range) age was 17 (6-27) years. At a median (range) follow-up of 31.9 (2.2-55.3) months, CMR per BICR any time before ISRT was 93% (26 of 28; 90% CI, 79.2-98.7; objective response rate [ORR], 100%), and 23 of 28 (82%) achieved CMR per BICR after 4 cycles of nivolumab plus BV (ORR, 96.4%). Kaplan-Meier estimates of EFS and progression-free survival rates at 3 years were 87% (3 of 18; 90% CI, 69.5-94.7) and 95% (1 of 18; 90% CI, 76.7-99.0), respectively. During induction, 22 patients (79%) had treatment-related adverse events, including 7 with grade 3 or 4 adverse events, 2 with anemia, 1 with neutropenia, and 6 with immune-mediated adverse events. Serious adverse events leading to discontinuation occurred in 2 patients.Conclusions and RelevanceThis nonrandomized clinical trial found that for children, adolescents, and young adults with low-risk, relapsed cHL, a transplant-free, risk-adapted, response-based approach with nivolumab plus BV and ISRT offered high CMR rates and high 3-year EFS rate, with a safety profile consistent with that of each agent used.Trial RegistrationClinicalTrials.gov Identifier: NCT02927769
Advancing drug development in myelodysplastic syndromes
McGraw, Kathy L. , Cunningham, Lea, Kim, Nina , Jen, Emily Y. , Ehrlich, Lori A. , Aplan, Peter D. , Garcia‐Manero, Guillermo , Foran, James M. , Zeidan, Amer M., Scott, Bart L. , Buckstein, Rena , Tinsley-Vance, Sara, Verma, Amit , Wroblewski, Tanya, Pavletic, Steven Z. , Zeidan, Amer M. , Verma, Amit , Kim, Nina , Jen, Emily Y , Ehrlich, Lori A , Aplan, Peter D , Garcia, Jacqueline S , Komrokji, Rami S , Sekeres, Mikkael A , Scott, Bart , Verma, Amit , Zeidan, Amer M , Mina, Alain , Calvo, Katherine R. , Garcia, Jacqueline S. , Dezern, Amy Elizabeth , Komrokji, Rami S. , Sekeres, Mikkael A. , Norsworthy, Kelly J.

Mayo Clinic

Blood Advances | December 30, 2024 | Volume: 9 | Issue: 5 | Pages: 1095-1104

10.1182/bloodadvances.2024014865 | PMID 39786387 Get It

Abstract Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the US Food and Drug Administration, (eg, luspatercept, ivosidenib, decitabine/cedazuridine, and imetelstat), there has been little progress in the development of truly transformative therapies for the treatment of patients with MDS. Challenges to advancing drug development in MDS are multifold but may be grouped into specific categories, including criteria for risk stratification and eligibility, response definitions, time-to-event end points, transfusion end points, functional assessments, and biomarker development. Strategies to address these challenges and optimize future clinical trial design for patients with MDS are presented here.
Interobserver Reliability of the 5-Point Deauville Score and SUV-Based Quantification of FDG PET/CT Scans in High-Risk Pediatric Hodgkin Lymphoma
Lee, Inki , Milgrom, Sarah A. , Pei, Qinglin , Renfro, Lindsay A. , McCarten, Kathleen M. , Schwartz, Cindy L. , Cole, Peter D. , Kelly, Kara M. , Im, Hyung‐Jun , Hoppe, Bradford S. , Cho, Steve Y.

Mayo Clinic

Clinical Nuclear Medicine Open | December 30, 2024 | Volume: 1 | Issue: 2 | Pages: No page available

10.1097/nm9.0000000000000011 Get It

Purpose In lymphomas, the Deauville score (DS) standardizes 18F-FDG PET treatment response assessments. We assessed interobserver agreement of the DS and developed a quantitative PET-based parameter to minimize subjectivity of response assessments. Methods PET scans performed within the Children’s Oncology Group AHOD0831 study were analyzed. One hundred one scans obtained after the first cycle of chemotherapy (PET1) and 83 obtained after the second cycle (PET2) were eligible for inclusion. Each scan was assigned a DS by 2 nuclear medicine radiologists and a Hodgkin lymphoma index (HLI), defined as the ratio of the tumor’s SUVmax or SUVpeak to the liver’s SUVmean. Cohen κ coefficient measured the rate of agreement of the DS assigned by the 2 radiologists. Receiver operating characteristic curves and the Youden index were used with the consensus DS to identify an optimal HLI cutoff value to distinguish PET-negative from PET-positive images. For each HLI cutoff value, sensitivity, specificity, and accuracy were calculated. Results Interobserver agreement in DS was moderate (PET1: κ = 0.480, P < 0.001; PET2: κ = 0.428, P < 0.001). On PET1, the optimal cutoff values for HLImax were 1.19 for DS2/DS3 and 1.78 for DS3/DS4, and for HLIpeak were 1.19 for DS2/DS3 and 1.44 for DS3/DS4. On PET2 images, the corresponding values were 1.18, 1.58, 0.94, and 1.26. The most accurate predictor was HLImax on PET2 when scans were dichotomized as DS1–DS3 versus DS4–DS5 (accuracy, 92.8%; sensitivity, 100%; specificity, 91.8%). Conclusion The HLI provides an objective, quantitative measure of disease response and thus may improve interreader agreement for lymphoma response assessments.
FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease
Mitsinikos, Tania , Aw, Marion , Godoy, Marcela , Ibrahim, Samar H. , Memon, Iqbal , Mohan, Neelam, Mouane, Nezha , Verduci, Elvira , Xanthakos, Stavra A. , Ibrahim, Samar H , Bandsma, Robert , Mann, Jake Peter , Porta, Gilda

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | December 27, 2024 | Volume: 80 | Issue: 3 | Pages: 397-407

10.1002/jpn3.12399 | PMID 39727048 Get It

AbstractAs rates of obesity rise worldwide, incidence of metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease, is increasing, worsening the burden of healthcare systems. The council of the Federation of International Societies for Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN) identified the topic of MASLD epidemiology, treatment, and prevention as a global priority issue to be addressed by an expert team, with the goal to describe feasible and evidence‐based actions that may contribute to reducing MASLD risk. The FISPGHAN member societies nominated experts in the field. The FISPGHAN council selected and appointed members of the expert team and a chair. The subtopics included in this manuscript were chosen through a consensus of the experts involved. We review the epidemiology, natural history, and screening and management. We further expand to relevant public health measures aimed at MASLD prevention, including identifying interventions that could reduce risk factors (environmental and iatrogenic), optimize maternal and newborn health, and support healthier lifestyles for older children and adolescents on a local, national, and international scale. While recognizing that various aspects of population health and public policy can shape MASLD risk, we also review what we can do on an individual level to support our patients to reduce the significant burden of this ever rising disease in pediatrics.
Position statement of the World Endoscopy Organization: Role of endoscopy in screening, diagnosis, and treatment of esophageal superficial squamous neoplasiaia
Hassan, Cesare , Goda, Kenichi, Iyer, Prasad G. , Awadhi, Sameer Al , Lehibi, Abed Al , Arantes, Vitor , Burgos, Herbert, Cerisoli, Cecilio L., Dawsey, Sanford, Fleischer, David, Fluxá, Fernando, Inoue, Haruhiro , John, Sneha , Khashab, Mouen A., Kothari, Shivangi , Lee, Yeong Yeh, Ngamruengphong, Saowanee , Sharara, Ala I. , Shimamura, Yuto , Varocha, Mahachai, Villa‐Gomez, Guido, Wang, Kenneth K. , Yip, Hon Chi , Sharma, Prateek , Lee, Yeong Yeh , Chiu, Philip Wai Yan , Emura, Fabian , G Iyer, Prasad, Kim, Gwang Ha , Shimamura, Yuto , Yip, Hon-Chi , Hassan, Cesare , Lee, Yeong Yeh , Antonelli, Giulio , Burgos, Herbert, Dawsey, Sanford, Draganov, Peter V. , González, Nicolás , Kashin, Sergey V. , Khashab, Mouen A. , Lee, Yeong Yeh, Remes Troche, José M , Varocha, Mahachai, Wang, Wen‐Lun

Mayo Clinic

Digestive Endoscopy | December 26, 2024 | Volume: 37 | Issue: 5 | Pages: 470-489

10.1111/den.14967 | PMID 39722219 Get It

Esophageal squamous cell carcinoma (ESCC) remains a significant global health challenge, being the sixth leading cause of cancer mortality with pronounced geographic variability. The incidence rates range from 125 per 100,000 in northern China to 1–1.5 per 100,000 in the United States, driven by environmental and lifestyle factors such as tobacco and alcohol use, dietary habits, and pollution. Major modifiable risk factors include tobacco and alcohol consumption, with a synergistic risk increase when combined. Nonmodifiable risk factors include previous diagnoses of head and neck squamous cell carcinoma (H&N SCC), achalasia, and prior radiotherapy. Prevention strategies must be tailored to specific regional burdens to efficiently allocate medical and financial resources. Gastrointestinal endoscopy is crucial in reducing ESCC burden through early detection and characterization of neoplastic changes, such as high‐grade dysplasia. Early diagnosis significantly improves survival rates, while endoscopic resection of noninvasive dysplasia can prevent ESCC onset, reducing treatment burden for advanced disease. Postresection surveillance can detect high‐risk metachronous lesions. Despite these benefits, endoscopic prevention faces challenges, including the lack of high‐level evidence supporting its efficacy, opportunity costs, the need for specialized training and techniques, and the requirement for advanced technology investments. This Position Statement from the World Endoscopy Organization (WEO) aims to address these challenges, supplying recommendations for the exploitation of endoscopic resources regarding the possible role of screening, quality, and training for the detection, characterization, resection, and surveillance of ESCC.
Expert consensus recommendations on dermoscopy proficiency standards for physician assistants: results of a modified Delphi survey
Young, Peter A. , Middleton, Hayden T. , Froiland, Christi, Keeter, Nicole, Sanders, Kim B., DiRuggiero, Douglas , Pettey, Adam A., Swanson, David C. , Marghoob, Ashfaq A. , McCleskey, Patrick E. , Seiverling, Elizabeth V. , Griffith, Cynthia Faires , Sanders, Kim B., Bae, Gordon Hyeonjin , Mostaghimi, Arash , Nelson, Kelly C.

Mayo Clinic

Journal of Dermatology for Physician Assistants | December 25, 2024 | Volume: 19 | Issue: 1 | Pages: 14-19

10.1097/jdpa.0000000000000047 Get It

Importance: Dermoscopy is increasingly recognized by skin cancer experts and professional leaders as an essential skill for physicians in dermatology and primary care. A substantial number of patients in both settings also receive care from physician assistants (PAs), who provide additional opportunities to evaluate patients with concerning skin lesions. Earning dermatology-specific credentials from the National Commission on Certification for PAs requires passing a written exam with dermoscopic content, and 77% of practicing PAs (all specialties) believe dermoscopy should be a standard element of their formal education. No published studies have identified precise learning objectives that would represent appropriate foundational proficiency in dermoscopy for PAs. Objective: We sought to identify common diagnoses with distinct dermoscopic features and delineate which of these represent appropriate proficiency expectations for early-career PAs in primary care and dermatology. Design, setting, and participants: A panel of 14 dermoscopists was assembled (8 dermatologists; 6 PAs), reflecting contributors to existing consensus statements on physician dermoscopy proficiency benchmarks, dermatologist-recommended competencies for PAs, and/or standardized test content for dermatology PAs. Panelists completed a modified Delphi consensus process involving electronic surveys and roundtable discussions. Main outcomes and measures: Consensus on which specific dermoscopic diagnoses reflect appropriate foundational proficiency expectations for PAs in both primary care and dermatology. Results: Twelve of 14 panelists (86%) reported using dermoscopy for over 12 years (mean: 15.5 y). All panelists completed 2 iterations of an electronic survey regarding 54 diagnoses, with 39 (72%) reaching a final consensus for inclusion in PA curricula and 15 (28%) being identified as non-priority items for early-career PAs. Panelists recommended 14 conditions for primary care PAs and 25 conditions for dermatology PAs. Conclusions and Relevance: Consensus achieved in this modified Delphi process identified diagnoses that represent pragmatic learning objectives to achieve foundational proficiency in dermoscopy for PAs in both primary care and dermatology. This list of validated objectives provides a consensus-based guide to help educators, supervising physicians, and professional leaders to cultivate specialty-appropriate dermoscopic proficiency among early-career PAs.